The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
The SWI/SNF complex in cancer — biology, biomarkers and therapy
Open accessAbstract
Cancer genome-sequencing studies have revealed a remarkably high prevalence of mutations in genes encoding subunits of the SWI/SNF chromatin-remodelling complexes, with nearly 25% of all cancers harbouring aberrations in one or more of these genes. A role for such aberrations in tumorigenesis is evidenced by cancer predisposition in both carriers of germline loss-of-function mutations and genetically engineered mouse models with inactivation of any of several SWI/SNF subunits. Whereas many of the most frequently mutated oncogenes and tumour-suppressor genes have been studied for several decades, the cancer-promoting role of mutations in SWI/SNF genes has been recognized only more recently, and thus comparatively less is known about these alterations. Consequently, increasing research interest is being focused on understanding the prognostic and, in particular, the potential therapeutic implications of mutations in genes encoding SWI/SNF subunits. Herein, we review the burgeoning data on the mechanisms by which mutations affecting SWI/SNF complexes promote cancer and describe promising emerging opportunities for targeted therapy, including immunotherapy with immune-checkpoint inhibitors, presented by these mutations. We also highlight ongoing clinical trials open specifically to patients with cancers harbouring mutations in certain SWI/SNF genes. Mutations in genes encoding subunits of the SWI/SNF chromatin-remodelling complexes occur in almost 25% of all cancers. Herein, Mittal and Roberts discuss the mechanisms by which these mutations might promote cancer and describe the associated vulnerabilities that provide opportunities for targeted therapy or immunotherapy with immune-checkpoint inhibitors. At least nine different genes encoding subunits of the SWI/SNF family of chromatin-remodelling complexes are recurrently mutated in cancer, and these mutations are collectively present in nearly 25% of cancers. Mutations in specific SWI/SNF genes are enriched in particular cancer types, suggesting differential roles for individual SWI/SNF components; consistent with this hypothesis, different SWI/SNF gene mutations confer distinct cancer vulnerabilities in mouse models. The tumour-suppressor activity of the SWI/SNF chromatin-regulatory complexes is most likely attributable to their roles in facilitating transcription factor function, which is central to cell-fate specification; however, roles of the complexes in facilitating DNA repair might also contribute. The identification of potential therapeutic vulnerabilities that arise from SWI/SNF gene mutations is leading to new areas of clinical investigation, including studies of immunotherapy in addition to kinase inhibitors and agents targeting mediators of DNA damage repair.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationComprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
The Biology of Chromatin Remodeling Complexes
Clapier, C. R., & Cairns, B. R. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.062706.153223 · Cited by 2,380
Burnside, R. D. (2015) · Cytogenetic and Genome Research · doi:10.1159/000438708 · Cited by 1,946
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
Versteege, I., Sévenet, N., Lange, J., Rousseau-Merck, M.-F., Ambros, P., Handgretinger, R., Aurias, A., & Delattre, O. (1998) · Nature · doi:10.1038/28212 · Cited by 1,556
Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,521
Cited by
Biomolecular Condensates and Cancer
Boija, A., Klein, I. A., & Young, R. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.003 · Cited by 327
Hepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 307
Xu, X., Peng, Q., Jiang, X., Tan, S., Yang, Y., Yang, W., Han, Y., Chen, Y., Oyang, L., Lin, J., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01020-1 · Cited by 276
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100167 · Cited by 126
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Ortmann, B. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000154 · Cited by 67
Shi, W., Wang, Y., Xu, C., Li, Y., Ge, S., Bai, B., Zhang, K., Wang, Y., Zheng, N., Wang, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35797-6 · Cited by 50
Mechanism of Action of the SWI/SNF Family Complexes
Chen, K., Yuan, J., Sia, Y., & Chen, Z. (2023) · Nucleus · doi:10.1080/19491034.2023.2165604 · Cited by 45
WSTF nuclear autophagy regulates chronic but not acute inflammation
Wang, Y., Eapen, V. V., Liang, Y., Kournoutis, A., Sherman, M. S., Xu, Y., Onorati, A., Li, X., Zhou, X., Corey, K. E., et al. (2025) · Nature · doi:10.1038/s41586-025-09234-1 · Cited by 30
Missense Variants Reveal Functional Insights Into the Human ARID Family of Gene Regulators
Deák, G., & Cook, A. G. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167529 · Cited by 20
“Mutations in the BAF complex promote tumorigenesis in multiple cancer types (reviewed in (20)).”
BackgroundRole of SWI/SNF chromatin remodeling genes in lung cancer development
Monterde, B., & Varela, I. (2022) · Biochemical Society Transactions · doi:10.1042/bst20211084 · Cited by 13
Comparative analysis of retroviral Gag-host cell interactions: focus on the nuclear interactome
Lambert, G. S., Rice, B. L., Maldonado, R. J. K., Chang, J., & Parent, L. J. (2024) · Retrovirology · doi:10.1186/s12977-024-00645-y · Cited by 5
Ferreira, M. A. D. M., & Silveira, W. B. D. (2024) · Biochemical Engineering Journal · doi:10.1016/j.bej.2024.109471 · Cited by 3
Impact of frequent ARID1A mutations on protein stability provides insights into cancer pathogenesis
(2025) · doi:10.1038/s41598-025-87103-7 · Cited by 2
Metadata
- Authors
- Mittal, P., & Roberts, C. W. M.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2020-04-17
- Volume
- 17
- Issue
- 7
- Pages
- 435-448
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3016379099
- Cited by
- 690
- References
- 171
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.